Smoking and adiponectin are individually associated with cardiometabolic pathologies. The present systematic review was carried out in order to summarize the association between the smoking status and circulating adiponectin levels. Methods: Original articles, restricted to epidemiological studies (by a cross-sectional, case-control and cohort study design) and intervention studies for adult humans, were screened for the years 1995-2010. All of the research group members then selected the eligible literature and assessed the articles in a structured systematic review manner. Results: There were 11 key studies, which included 9 articles with a cross-sectional design and 2 articles with an intervention design. Most cross-sectional studies reported lower levels of adiponectin in current smokers than in non/never smokers and/or ex-smokers, while 2 studies reported a non-significant difference in adiponectin between male smokers and non-smokers. The two intervention studies, conducted in patients on 9-week bupropion treatment and 6-month non-pharmacological treatment, reported that smoking cessation increased the adiponectin levels. Conclusion: This review suggests that there is a decreased adiponectin level in current smokers and this reduction can be reversed by quitting smoking. More studies are required to confirm the findings and elucidate the biological mechanisms underlying the association between the smoking status and adiponectin levels. 
Introduction
The health risks of tobacco smoking have been established for decades worldwide, and regulating smoking remains a public health challenge [1] [2] [3] . Smoking is a well-known atherosclerotic risk factor, although the underlying mechanisms are complex and incompletely clarified [1] [2] [3] . On the other hand, meta-bolic syndrome has recently been given sociomedical attention due to its increasing prevalence and atherosclerotic burden 4, 5) . Of note, smoking is reportedly associated with the development of metabolic syndrome, presumably via a pathway leading to the development of cardiovascular disease [6] [7] [8] [9] . Metabolic syndrome is an obesity-related disorder, and various adipocytokines play crucial roles in the pathophysiology of metabolic syndrome 10) . In particular, adiponectin is a key protein secreted by adipocytes, which can contribute to improving cardiometabolic outcomes 11, 12) . Namely, a decrease in the circulating adiponectin concentration is reported to be associated with cardiometabolic disorders 11, 12) ; there-As the first step, all candidate bibliographies that were searched were screened according to the title and abstract by at least two researchers: one researcher checked the appropriateness of publications independently of another researcher, and subsequently, the compatibility between the two researchers was confirmed. When the researchers' opinions matched, the articles were considered to be eligible for the next step or were omitted. If the researchers' opinions did not match, the eligibility of articles was determined during a discussion. In this step, the literature was restricted to epidemiological studies (by a cross-sectional, case-control and cohort study design) and intervention studies. Only original articles focusing on the association between smoking and adiponectin were considered as appropriate publication types. As the study populations, when there were the studies of pregnant subjects and those with specific disease conditions such as severe cardiopulmonary disease, psychological disease or collagen disorders, the articles were excluded.
As the second step, the text contents of the articles were assessed using a sheet according to the following terms of the study: the study's aim, subjects, methodologies (i.e., the regulation of bias and confounding factors, statistical analysis) and the presentafore, the association between smoking and adiponectin is of great interest. The present work aimed to summarize the smoking-adiponectin association, based on a systematic review of the existing literature.
Methods
The process of the study is shown in Fig. 1 . The database search engine, PubMed, was utilized to identify the relevant literature published between January 1995 and December 2010 (studies on adiponectin have been seen since about 1995). The following key words were used to search for 'smoking'-related publications: 'smok ＊ ', 'tobacco' and 'nicotine', with the 'Title' or 'MeSH Major Topic'. For 'adiponectin', the following key word was used: 'adipo ＊ ' (because adiponectin is also referred to as other expressions such as AdipoQ, adipocyte complement-related protein of 30kDa [Acrp30] or adipose most abundant gene transcript 1 [apM1]), with the 'Title' or 'MeSH Major Topic'. The 'smoking'-related publications and 'adipo ＊ ' -related publications were coupled in a subsequent search. The search was then restricted to 'humans', 'adult ＞19 years' and 'English' as well as 'Japanese' articles only. The publication type of 'editorial' and 'letter' was also excluded. 21) . Even though there appeared to be relatively many studies in Asian populations, similar trends were observed in the association between smoking and adiponectin across countries.
Measures of Interests
The total adiponectin levels in the circulation were measured in 10 studies. While high-molecularweight adiponectin in the circulation was used in one study 14) , this report was included in the present systematic review because the high-molecular-weight type is currently considered an active form of adiponectin 25) . The smoking status was assessed mainly by questionnaire methods, while one study simultaneously used an objective measure to evaluate the smoking exposure (e.g., cotinine) 15) .
Study Designs
A cross-sectional design was applied in 9 studies 14, [17] [18] [19] [20] [21] [22] [23] [24] , and an intervention design was used in the other 2 studies 15, 16) . The intervention studies used the following treatment: a 9-week pharmacological approach (150 mg sustained-release bupropion twice daily) for non-specific subjects 15) and a 6-month nonpharmacological approach to quit smoking for patients with stable angina pectoris 16) . While most of the cross-sectional studies were conducted in healthy and non-specific diseased populations recruited from general health check-ups or advertisements for the study participation 14, [17] [18] [19] [20] [22] [23] [24] , only one study focused on patients with coronary artery disease 21) .
Gender Differences
Except for 2 studies 15, 22) , 7 studies (including one intervention study) reported the results for males only 14, 16, 17, 19, 21, 23, 24) and 2 studies reported the results separately for males and females 18, 20) . Although there were only a few studies of females, similar trends were observed in the association between smoking and adiponectin in both genders.
Smoking-Related Information
A few studies assessed the detailed information on smoking habits such as non/never, ex-and current smoking, as well as the amount and duration smoked. A linear trend of adiponectin from high to low levels, corresponding to non/never, ex-to current smokers, was reported 17, 20, 21, 23) . Most studies revealed that the adiponectin levels in non/never and ex-smokers were relatively high compared to current smokers 17, 20, 23) while, in one study, the adiponectin levels were lower in non/never, current and ex-smokers, in that order 21) . In terms of smoking intensity, the adiponectin levels tion of the results. The terms were scored on a 1-5 point scale, and the rates were calculated for each article. A score of more than 3 points (60%) was considered to indicate appropriate content. In this step, each article was scored separately by two researchers. One researcher was the chief leader in charge and the other was the sub-leader. After assessment by the chief leader, the results were confirmed independently by the sub-leader. When the two researchers' results matched, the articles were considered as either eligible for the next step or were omitted. If the researchers' results did not match, then the eligibility of the articles was again determined during a discussion.
During the third step, the two researchers filled out a form regarding the abstract, abstract table, summary table and summary points for each article that the same two researchers had assessed in the second step. Thereafter, all the research group members further reviewed the form and contents of the articles, finally establishing the appropriateness of the articles. Throughout this systematic review, the key articles were summarized with regards to the association between the smoking status and circulating adiponectin levels.
In addition, the level of evidence was discussed using 5 levels ranking from 1 to 5 according to the quality of evidence, as developed by the US Preventive Services Task Force 13) . After the final summary was completed, the chief leader provided the assumed level of evidence to all the research group members. The members also independently declared the level of evidence, and the level of evidence was finally determined based on their consensus.
Results
Although 52 articles were searched, only 12 articles were considered candidates after the first step. During the second step, one article did not achieve the appropriate score. In the third final step, there remained 11 appropriate articles, which were finally selected for our systematic review.
A summary of the articles is listed in Table 1 . The general trends were lower levels of adiponectin in current smokers than in non/never smokers and/or exsmokers 14, 17, 18, [20] [21] [22] [23] [24] , while 2 studies reported a nonsignificant difference in the adiponectin levels between male smokers and non-smokers 18, 19) (one study reported a significant difference in a female population 18) ). Furthermore, smoking cessation intervention resulted in an increase in the adiponectin levels 15, 16) . There were 5 studies reported from Japan 14, 16, 20, 23, 24) , 3 adjustments for these factors did not largely change our present findings. Accordingly, even though there were limited published articles and/or no randomized control trials focusing on the association between the smoking status and adiponectin levels (thus, the level of evidence for the present review was not very high), it is valuable to note that relatively consistent data have been reported. These findings may suggest important clinical implications. There are currently no reports showing that the modulation of adiponectin, resulting from the modification of smoking habits, affects the development of metabolic syndrome, atherosclerosis and cardiovascular disease; however, smoking habits are modifiable, so it is expected that smoking cessation can prevent future negative cardiometabolic outcomes by increasing the adiponectin levels [6] [7] [8] [9] . Several biological reasons for the lower adiponectin levels by smoking are considered in the present review. Nicotine itself inhibits the expression of the adiponectin gene in adipocytes 23, 31) . Smoking also provokes oxidative stress and inflammatory cytokines (i.e., tumor necrosis factor-alpha), especially by which the expression of adiponectin gene is inhibited 23, 32) . Smoking is known to impair vessel walls, and adiponectin can accumulate in these walls; therefore, adiponectin levels may be reduced in the circulation due to their enhanced consumption by the vessel walls 33) . In our present review, significant relationships between smoking and adiponectin were unaffected even after adjusting for obesity-related traits in the analyses 14, 15, 17, 18, [21] [22] [23] [24] . This could support the presence of mechanisms regarding not only adipose tissues, but also other tissues, including vessel walls. We think that both the nicotine and smoking-induced pathways may directly and indirectly be associated with low adiponectin levels in smokers.
In addition, smoking cessation through intervention promptly induced increases in adiponectin levels 15, 16) . This result may indicate a mechanistically rapid response to smoking exposure. Whereas most studies reported lower adiponectin levels in current smokers than in ex-smokers 17, 20, 23) , one cross-sectional study reported lower adiponectin levels in ex-smokers than in current smokers 21) . This may also imply the presence of a slow response to the reversibility of the reduced adiponectin levels. In one study demonstrating a non-significant difference in adiponectin levels between smokers and nonsmokers, the nonsmokers included those who had quit at least 6 months prior 19) . There can be a continued influence of the smoking status on adiponectin levels after quitting smoking 20) . If there is a slow reversibility of adiponecin non/never, ex-and light smokers were higher relative to the levels in heavy smokers 14) and, in other studies, the adiponectin levels tended to be lower in heavy smokers relative to light smokers among current male smokers who had lower adiponectin levels than non/never or ex-smokers 17, 20) . Another study also reported that although the Brinkman index was not associated with the adiponectin levels, the number of cigarettes smoked per day was inversely associated with the adiponectin levels among current smokers 23) . An additional study reported that men who had quit smoking for more than 20 years and women for 10 years could have adiponectin levels similar to those observed in nonsmokers 20) .
Other Lifestyle-Related Factors
Since not only smoking, but also other lifestylerelated factors, can affect adiponectin levels [26] [27] [28] , several studies took other lifestyle-related factors into account, such as dietary components (e.g., vegetable intake, eating-out habits, energy intake) 20, 24) , alcohol consumption 14, 17, 20, 21, 23, 24) and exercise 20, 24) . There were several studies where obesity-related traits such as the body mass index were included as an adjusted variable in the analysis model 14, 15, 17, 18, [21] [22] [23] [24] ; however, even when these factors were considered in the analyses, the relationship between smoking and adiponectin was not largely affected. In addition to the obesityrelated traits, when subject age was also adjusted in the analyses, the relationship between smoking and adiponectin remained unaffected 14, 15, 17, 18, [21] [22] [23] [24] .
Level of Evidence
Although intervention studies were included in the reviewed articles, these studies were basically of a single-arm group. There were no studies corresponding to randomized controlled trials, well-designated controlled trials, well-designated cohort studies, casecontrol analytical studies, or studies showing marked changes in some outcomes. The evidence for the reviewed articles was thus considered to be at level 3.
Discussion
The present review demonstrated, as a whole that, 1) there is a lower adiponectin level in current smokers relative to non/never smokers and/or ex-smokers, with a possible dose-response relationship, and 2) there is a possible reversibility of this association after smoking cessation. Although basic confounders such as age 29, 30) and obesity-related traits 11, 12) , in addition to other lifestyle-related factors, can potentially affect adiponectin levels, several studies revealed that the trials on medications for tobacco dependence treatments. tin levels after smoking cessation, the definition of 'nonsmokers' by the study may make a difference in the adiponectin levels. Further research is warranted to clarify the deeper mechanism(s) underlying the association between smoking and adiponectin.
Our study had several limitations. Most reviewed studies evaluated the smoking status on the basis of questionnaires, not objective measures, although this methodology is often used in this research field. The categories of the smoking status were not always identical between studies. Most studies did not include information about the Brinkman index and the duration of smoking. The assay system used to measure the circulating adiponectin levels could also be different among studies; thus, the consistency of the findings should be given some consideration. Moreover, the follow-up periods of only 2 intervention studies reviewed 15, 16) were short. Smoking cessation can cause weight gain and/or glucose intolerance [34] [35] [36] . Such changes of metabolic parameters as body mass index, glucose and hemoglobin A1c were not reported during the study period of the 2 interventions (as shown in Table 1 ). One intervention study reported that changes in glucose and obesity-related traits were not significantly correlated with the change in adiponectin levels in multivariate-adjusted analysis 15) and another intervention study reported that changes in glucose and obesity-related traits were not extracted as variables significantly correlated with the change of adiponectin levels in the model of multivariate-adjusted analysis 16) ; however, longer follow-up studies remain necessary to determine the effect of smoking cessation on adiponectin. In addition, studies with adjustments for various factors affecting the smoking status and adiponectin levels were limited. Although similar trends were likely observed in the association between smoking and adiponectin in men and women, there are only a few studies of women to define the gender difference in their association. These issues must be addressed in future work.
In summary, the present systematic review suggests that there is a lower adiponectin level in current smokers relative to non/never smokers and smoking cessation can increase adiponectin levels. Further studies are needed to confirm these findings and to elucidate the biological mechanisms underlying the relationship.
